VIVUS Press Releases

Date Title Links
Toggle Summary VIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation
CAMPBELL, CA -- (Marketwired) -- 07/05/17 -- VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Actavis Laboratories FL (Actavis) resolving patent litigation related to Qsymia® (phentermine and topiramate extended-release) capsules CIV.
Toggle Summary VIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi
VIVUS to Receive Commercial Rights to Africa, the Middle East, Turkey and the Commonwealth of Independent States, Including Russia
Toggle Summary VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH)
CAMPBELL, CA , and SAN CARLOS, CA -- (Marketwired) -- 01/09/17 -- VIVUS, Inc. ( NASDAQ : VVUS) and Selten Pharma, Inc. , announced VIVUS' acquisition from Selten of exclusive, worldwide rights for the development and commercialization of tacrolimus and ascomycin for the treatment of Pulmonary